Friday 15 October 2010

Kennedy Krieger Institute: Kennedy Krieger Institute Launches First Phase II Clinical Trial of Heart Disease Treatment for Duchenne Muscular Dystrophy

Kennedy Krieger Institute: Kennedy Krieger Institute Launches First Phase II Clinical Trial of Heart Disease Treatment for Duchenne Muscular Dystrophy: "Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD). Made possible by a $545,000 grant from Pilot Trials Now, an innovative DMD initiative organized and managed by Charley’s Fund Inc. and The Nash Avery Foundation, with additional support from Pfizer Inc., the study will examine whether Revatio (sildenafil) improves cardiac function for those affected by the most common fatal genetic disorder in the world."

No comments:

Post a Comment